Back to search

Peptide record

TPDB92373

At1 Ponericin-W1 (11-25) Antibacterial Anticancer Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92373
At1 Ponericin-W1 (11-25)
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-KLLPSVVGLFKKKKQ-NH2
Physicochemical Analysis
C82H145N21O18
ARNDCEHIMTWY
K
1713.18
11.12
5
0
6
+5
3.45
-0.213
116.67
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
1
Q
1
G
0
H
0
I
3
L
5
K
0
M
1
F
1
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 1 H: 0 I: 0 L: 3 K: 5 M: 0 F: 1 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
15
C82H145N21O18
1713.18
11.12
+5
3.45
-0.213
Amidation
L
Linear
Acetylation
Antimicrobial
Synthetic
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 > 100 µM
Anticancer
100 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 >100 µM
Anticancer
100 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay

Source & Reference

CancerPPD 2.0
CancerPPD2
2022